It’s not all bad… we have multiple NDA’s. I
Post# of 155139
(Total Views: 842)
Posted On: 03/31/2022 3:10:02 PM
It’s not all bad… we have multiple NDA’s. I didn’t want to believe that but Dr. Kelly stated that. It looks like they have broke down the ability of partnering by the indication and that is the future. Even breaking down HIV into multiple partnerships. Ie. Combo, Mono, Prep and maybe even cure. Is this because they are locked into a partnership in Combo that has only performance reasons to break that partnership in HIV Combo? Can’t even talk buy-out because of our first partnership?
I have to say that the immense future possibilities being cut in half if we can negotiate a 50/50 deal on any indication like we did with HIV Combo could be still lucrative. Our future indications that we can partner with isn’t the best direction forward I had hoped for. Not all is lost with partners if it helps us move the timing and speed of indications foreword on different levels and speed of developing investments by individual indications. There has to be a benefit to move quickly like partnering on a few indications in what seems like a very rushed way.
I still hope that we partner only a few indications and hopefully keep some indications for ourselves when we do achieve revenue or large pre payments for any of the partnerships. My hope is still alive that we can grow ourselves into a pharmaceutical company.
It’s all in how you word our individual partnership contracts and if our current management sees a future that’s worth growing or is looking to just get out of the biotech world the easy way in selling all indications quickly and throwing in the towel on growth of becoming a pharmaceutical company. Having multiple NDA’s is a direction that says individual indications have been separated and we will negotiate the best deals possible both here and internationally. It leaves hope for us and is encouraging to see the separation of indications and not just a roll over and you win… buy-out… of Cytodyns potential. It gives us the potential to see large value still to be realized. So let’s hope we negotiate with a future eye looking to a bright future as a pharmaceutical company. Because when you run the numbers… being our own pharmaceutical company is where the money and return on our investment is best realized.
I have to say that the immense future possibilities being cut in half if we can negotiate a 50/50 deal on any indication like we did with HIV Combo could be still lucrative. Our future indications that we can partner with isn’t the best direction forward I had hoped for. Not all is lost with partners if it helps us move the timing and speed of indications foreword on different levels and speed of developing investments by individual indications. There has to be a benefit to move quickly like partnering on a few indications in what seems like a very rushed way.
I still hope that we partner only a few indications and hopefully keep some indications for ourselves when we do achieve revenue or large pre payments for any of the partnerships. My hope is still alive that we can grow ourselves into a pharmaceutical company.
It’s all in how you word our individual partnership contracts and if our current management sees a future that’s worth growing or is looking to just get out of the biotech world the easy way in selling all indications quickly and throwing in the towel on growth of becoming a pharmaceutical company. Having multiple NDA’s is a direction that says individual indications have been separated and we will negotiate the best deals possible both here and internationally. It leaves hope for us and is encouraging to see the separation of indications and not just a roll over and you win… buy-out… of Cytodyns potential. It gives us the potential to see large value still to be realized. So let’s hope we negotiate with a future eye looking to a bright future as a pharmaceutical company. Because when you run the numbers… being our own pharmaceutical company is where the money and return on our investment is best realized.
(10)
(0)